Dallas, TX: ReportsandReports announce Johnson & Johnson: PharmaVitae Profile
Market Research Report in its Store.
Browse complete Report at : http://www.reportsandreports.com/reports/8183-johnson-johnson-pharmavitae-profile.html
This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
• Benchmark Johnson & Johnson’s performance against key rivals in the prescription pharmaceutical sector
• Analyze how J&J will implement life-cycle management strategies across its portfolio as a means to combat patent expiries and generic competition
• Assess J&J’s diverse healthcare offering and how this will act to maintain operating profit growth despite a forecast decline in Rx drug revenue
• Table Of Contents
• ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
• Chapter 1 About this profile 3
• PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly update 3
Company introduction 3
Company sales 4
Company financials 4
Key products 4
Data sourcing 4
Sales data 4
Analyst consensus 4
• Chapter 2 Executive summary 5
• Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003-15 6
Financial performance, 2003-15 7
Johnson & Johnson: PharmaVitae forecasts at a glance 8
Strategic insight 9
Managing the boom & bust of ‘blockbuster’ drugs 9
US small molecule drug sales increase generic exposure 9
Lifecycle management will minimize loss from key products 9
Pipelines in a product-critical for growth of a company on J&J’s scale 11
Despite challenges, J&J’s outlook appears robust 12
Performance to 2015 will be clear by 2012 12
Diversified business balances risk 14
Wide range of strategic options to seek growth 15
SWOT analysis 18
Strengths 18
Weaknesses 19
Opportunities 20
Threats 21
• Table of Contents 22
• Table of figures 24
• Chapter 3 Quarterly news update 25
• Key findings 25
Latest quarterly sales 26
Latest comment 27
Q1 2010 27
Hope for an Alzheimer’s breakthrough remains despite Dimebon’s failure 27
MRSA drug receives European setback, J&J returns rights 28
Latest prescription pharma product news 30
Q2 2010 30
Q1 2010 30
Q4 2009 30
Q3 2009 31
Q2 2009 33
Q1 2009 34
Latest corporate news 36
Q1 2010 36
Q1 2010 36
Q4 2009 37
Q3 2009 37
Q2 2009 37
Q1 2009 38
Future product milestones 39
• Chapter 4 Company introduction 40
• Key findings 40
Background 41
Key corporate developments 41
M&A history 42
M&A strategy 44
Current corporate structure 45
• Chapter 5 Company sales 46
• Key findings 46
Prescription pharmaceutical sales and growth rate analysis, 2003-15 47
Product analysis 49
Product analysis, 2003-09 50
Product analysis, 2009-15 54
Therapy area analysis 59
Geographic analysis 63
Launch/core/expiry analysis 65
Explanation of launch/core/expiry analysis 65
Launch analysis, 2009-15 66
Core analysis, 2009-15 68
Expiry analysis, 2009-15 69
Generics analysis, 2009-15 71
Launch/core/expiry configuration, 2009-15 72
Molecule type analysis 73
Externalization analysis 76
• Chapter 6 Company financials 79
• Key findings 79
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09 80
Operating costs and profit analysis 81
Operating costs and profit analysis, 2003-09 82
Operating cost ratio and profit margin analysis, 2003-09 83
Operating cost ratio and profit margin analysis, 2009-15 84
Operating costs and profit analysis, 2009-15 85
• Chapter 7 Key products 87
• Key findings 87
Overview 88
Xarelto 89
Summary 89
Sales forecast 90
US launch forecast at the end of 2010 90
Set to revolutionize anticoagulant management 90
Attractive product profile will aid market success 91
Regulatory hurdles remain 91
Invega franchise 93
Summary 93
Sales forecast 94
Limited switching from Risperdal 94
Invega Sustenna will build upon Risperdal Consta’s success 95
Generic Invega assumed from 2012 95
Simponi 96
Summary 96
Sales forecast 97
Velcade 98
Summary 98
Sales forecast 99
Growth driven by label expansion 99
Takeda prevented J&J from acquiring Millennium 100
Remicade 101
Summary 101
Sales forecast 102
J&J markets Remicade in the US only 102
Humira has slowed growth of Remicade sales 102
New launches will maintain the growth of J&J’s I&I franchise 103
Procrit 104
Summary 104
Sales forecast 105
Decline as market share lost to Aranesp from 2002 105
Safety concerns have hit the wider ESA market 105
Further competition limited to ex-US markets for now 106
Risperdal franchise 107
Summary 107
Sales forecast 108
Success driven by first to market and favorable side effect profile 108
US generics hit Risperdal sales from June 2008 109
Additional products aimed at retaining patients within JNJ’s portfolio 109
Prezista 111
Summary 111
Sales forecast 112
Growth strengthened by earlier use 112
Close fit with additional HIV products 112
• Chapter 8 Appendix 114
• R&D pipeline 114
Remicade sales reconciliation 116
References 116
Abbreviations 117
Exchange rates 118
About Datamonitor 119
About Datamonitor Healthcare 119
Datamonitor consulting 119
Disclaimer 121
• List of Tables
• Table 1: Johnson & Johnson – PharmaVitae forecasts at a glance 8
Table 2: Johnson & Johnson quarterly sales ($m), Q408-Q409 26
Table 3: Johnson & Johnson future product milestones, 2010-12 39
Table 4: Johnson & Johnson product portfolio overview ($m), 2003-09 50
Table 5: Johnson & Johnson product portfolio overview ($m), 2009-15 54
Table 6: Johnson & Johnson prescription pharmaceutical sales by therapy area ($m), 2009-15 62
Table 7: Johnson & Johnson prescription pharmaceutical sales by geographic region ($m), 2009-15 64
Table 8: Johnson & Johnson launch portfolio overview ($m), 2009-15 66
Table 9: Johnson & Johnson core portfolio overview ($m), 2009-15 68
Table 10: Johnson & Johnson expiry portfolio overview ($m), 2009-15 69
Table 11: Johnson & Johnson expiry portfolio overview ($m), 2009-15 71
Table 12: Johnson & Johnson prescription pharmaceutical sales by molecule type ($m), 2009-15 75
Table 13: Johnson & Johnson prescription pharmaceutical sales by source ($m), 2009-15 78
Table 14: Total Johnson & Johnson sales by business unit ($m), 2003-09 80
Table 15: Johnson & Johnson operating revenue/cost analysis ($m), 2003-09 82
Table 16: Johnson & Johnson operating cost ratio analysis (% of total revenues), 2003-09 83
Table 17: Johnson & Johnson operating cost ratio analysis (% of total revenues), 2009-15 84
Table 18: Johnson & Johnson operating revenue/cost analysis ($m), 2009-15 85
Table 19: Johnson & Johnson Key products overview 88
Table 20: Xarelto: overview 89
Table 21: Xarelto]: sales forecast ($m), 2009-15 90
Table 22: Invega: overview 93
Table 23: Invega franchise: sales forecast ($m), 2009-15 94
Table 24: Simponi: overview 96
Table 25: Simponi: sales forecast ($m), 2009-15 97
Table 26: Velcade: overview 98
Table 27: Velcade: sales forecast ($m), 2009-15 99
Table 28: Remicade: overview 101
Table 29: Remicade: sales forecast ($m), 2009-15 102
Table 30: Procrit: overview 104
Table 31: Procrit: sales forecast ($m), 2009-15 105
Table 32: Risperdal: overview 107
Table 33: Risperdal: sales forecast ($m), 2009-15 108
Table 34: Prezista: overview 111
Table 35: Prezista: sales forecast ($m), 2009-15 112
Table 36: Johnson & Johnson’s R&D pipeline (Phase I-registration) 114
Table 37: Total Remicade sales forecast ($m), 2009-15 116
Table 38: Exchange rates, 2010 118
ABBREVIATIONS
Browse : Healthcare Market Research Reports
at : http://www.reportsandreports.com/cat/healthcare-market-research.html
Browse : Datamonitor Market Research Reports
at : http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html
Browse all Newly Published Market Research Reports
http://www.reportsandreports.com/LatestReport.aspx
Related Reports:
Browse all :Johnson & Johnson Vision Care, Inc Market Share Analysis
at : http://www.reportsandreports.com/reports/15620-johnson-johnson-vision-care-inc-market-share-analysis.html
Browse all : Johnson & Johnson Pharmaceutical Research & Development, LLC-Deals & Alliances Report
at : http://www.reportsandreports.com/reports/31574-johnson-johnson-pharmaceutical-research-development-llc-deal.html
Browse all : Johnson & Johnson-Detailed Product Pipeline
at :http://www.reportsandreports.com/reports/3885-johnson-johnson-detailed-product-pipeline.html
Browse all : Johnson & Johnson-Deals & Alliances Report
at : http://www.reportsandreports.com/reports/4338-johnson-johnson-deals-alliances-report.html
Browse all : Johnson & Johnson to Acquire Mentor Corporation: Expanding Presence in the Aesthetic Devices Market
at : http://www.reportsandreports.com/reports/14504-johnson-johnson-to-acquire-mentor-corporation-expanding-presen.html
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
